 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
RxSight, Inc. (RXST), a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally.
It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power.
RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors.
The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Please note, this stock reports earnings on Wednesday, February 28th.
RxSight reported a loss of $0.26 per share on revenue of $28.58 million for the fourth quarter ended December 2023. The consensus estimate was a loss of $0.36 per share on revenue of $27.43 million. The company beat expectations by 13.33% while revenue grew 77.65% on a year-over-year basis.
With a positive earings report, analysts have upgraded the stocks share prices and should be a strong investment.
Entry Point: $56.00
Trading Range: $14.14 - $58.21
Stop Loss: $53.20
Target Price: $61.60
